Perfusion infusion: WuXi Biologics opens disposable plant as part of $150m expansion

By Dan Stanton contact

- Last updated on GMT

The new plant is in WuXi CIty, China. Image: iStock/lighight
The new plant is in WuXi CIty, China. Image: iStock/lighight

Related tags: Wuxi biologics, Biotechnology

WuXi has responded to a global demand for perfusion technologies by opening a commercial scale manufacturing site in China with two 1,000L disposable bioreactors.

WuXi Biologics commenced operations yesterday at a new biomanufacturing plant in WuXi City, about 100km west of Shanghai, China.

The plant boasts two 1,000L single-use bioreactors offering perfusion processes to the contract manufacturing organisation’s (CMO) biopharma customers.

Compared to traditional batch-fed biomanufacturing processes, perfusion allows the continuous feeding and harvesting of biologics like monoclonal antibodies for several months at a time, and according to WuXi there is large demand for such technologies.

“Globally there is limited capacity,”​ Dr. Chris Chen, CEO of WuXi Biologics, told Biopharma-Reporter, adding the new facility is the largest single-use perfusion biomanufacturing facility in Asia and will cater for “great needs”​ in the space.

Single-use perfusion technologies are viewed as an important advance in the continuous manufacture of monoclonal antibodies​ and vaccines​, but continuous downstream processes are less established with fewer off-the-shelf options available to manufacturers and limited technologies bridging the gap with the upstream.

“We are developing the continuous purification technologies together with vendors,” ​said Chen but the firm – and industry – is challenged by the fact continuous chromatography hardware isn't readily available.

The opening of the plant itself is the first part of a $150m (€134m) investment in WuXi City announced in 2014, with construction beginning in May 2015​.

Another biomanufacturing suite will house fourteen 2,000L disposable bioreactors for batch-fed cell culture, set to begin operations early next year.

Cell banking development ups and downs in the US

Meanwhile, WuXi recently told us it is expanding its US cell line development services at its Philadelphia, Pennsylvania to be able to handle 100 projects per year.

“We just brought online five suites for cell banking, managing 80 banking projects per year,”​ a spokesperson said.

However, the firm also confirmed it has “stopped cell bank storage services in US and expanded them in China.”

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us

Products

View more

Webinars